REFERENCES
| Part 1: What's the Buzz: Standard & Emerging Interferon/RBV Anti-HCV Treatments |
|
| Presenter | Poster |
| Adrian M. Di Bisceglie, MD, FACP | 337. Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following sustained virologic response (SVR) to HCV therapy: a prospective 5 year cohort study. A. M. Di Bisceglie; S. L. George; K. L. Mihindukulasuriya; J. Hoffmann; B. R. Bacon View Abstract PDF |
| Bruce R. Bacon, MD | LB18. Use of daily Interferon Alfacon-1 (Infergen®, CIFN) plus ribavirin (RBV) in patients infected with hepatitis C (HCV) who are nonresponders to previous pegylated interferon plus RBV therapy: 24-week data from the DIRECT Trial. B. Bacon; A. Regev ; R. Ghalib ; G. Morelli ; K. Rothstein ; T. Hassanein ; M. Shiffman; B. Murphy ; Y. Xu View Abstract PDF |
| David R. Nelson, MD | 1136. Sustained Virologic Response Rates with albumin interferon alfa-2b in Combination with Ribavirin in Non-responders to Prior Interferon Therapy: Interim Results from a Phase 2 Study . D. Nelson; V. Rustgi; V. Balan; M. Sulkowski; J. McHutchison; G. L. Davis; L. Lambiase; R. Dickson; R. Yu; L. Novello; W. Freimuth; M. Subramanian View Abstract PDF |
| David R. Nelson, MD | 1141. Interim Antiviral and Safety Data with albumin interferon alfa-2b Combined with Ribavirin in a Phase 2b Study Conducted in a Genotype 1, IFN-naive, Chronic Hepatitis C Population . J. McHutchison; S. Zeuzem; Y. Benhamou; D. Shouval; V. Bain; S. Pianko; R. Flisiak; M. Grigorescu; V. Rehak; E. Yoshida; K. Kaita; P. Cronin; E. Pulkstenis; M. Subramanian View Abstract PDF |
Top |
|
| Part 2: Current and Emerging Treatments for Chronic HBV and HCV |
|
| Presenter | Poster |
| Robert G. Gish, MD | 109. Entecavir Maintained Virologic Suppression Through 3 Years of Treatment in Antiviral-Naive HBeAg(+) Patients (ETV 022/901). T. Chang; Y. Chao; S. Kaymakoglu; H. Cheinquer; M. Pessoa; R. Gish; F. Poordad; J. Yang; H. Brett-Smith; R. Hindes View Abstract PDF |
| Robert G. Gish, MD | 110. Assessment At Three Years Shows High Barrier To Resistance Is Maintained In Entecavir-Treated Nucleoside Naive Patients While Resistance Emergence Increases Over Time In Lamivudine Refractory Patients. R. J. Colonno; R. E. Rose; K. Pokornowski; C. J. Baldick; K. Klesczewski; D. Tenney View Abstract PDF |
| Robert G. Gish, MD | 992. Hepatitis B Surface Antigen Loss in Antiviral-Treated Patients with HBeAg(+) Chronic Hepatits B (CHB) Infection: Observations from Antiviral-Naive Patients Treated with Entecavir (ETV) or Lamivudine (LVD) . R. Gish; T. Chang; C. Lai; R. de Man; A. Gadano; F. Poordad; J. Zhu; J. Yang; H. Brett-Smith View Abstract PDF |
| Stefan Zeuzem, MD | 92. Combination of Telaprevir (VX-950) and Peg-IFN-alfa Suppresses Both Wild-type Virus and Resistance Variants in HCV Genotype 1-Infected Patients in a 14-day Phase 1b study. T. Kieffer; C. Sarrazin; J. Miller; S. Traver; Y. Zhou; D. Bartels; B. Hanzelka; U. Muh; C. Lin; H. Reesink; A. Kwong; S. Zeuzem View Abstract PDF |
| Paul J. Pockros, MD | 1133. Impact OF Taribavirin and Ribavirin Exposure on Efficacy and Anemia Rates When Combined with Pegylated Interferon Alfa-2b in the Treatment of Chronic HCV. I. Jacobson; P. Pockros; Y. Benhamou; R. Esteban-Mur; Y. Lurie; R. Flisiak; N. Afdhal; Y. Kim; Y. Xu; B. Murphy View Abstract PDF |
| Paul J. Pockros, MD | 1146. Rapid Virologic Response (RVR) Is Enhanced by Higher Drug Exposure Among Patients Receiving Taribavirin in Combination with Pegylated Interferon alfa-2b for the Treatment of HCV Infection. M. L. Shiffman; M. Rodriguez-Torres; S. Gordon; M. Palmer; P. Pockros; C. Trepo; Y. Kim; B. Murphy View Abstract PDF |
Top |
|
| Part 3: Spotlight on New and Investigational Agents |
|
| Presenter | Poster |
| Ching-Lung Lai, MD | 91. Two-Year Results from the GLOBE Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs. Lamivudine. C. Lai; E. Gane; C. Hsu; S. Thongsawat; Y. Wang; Y. Chen ; E. J. Heathcote; J. Rasenack ; N. Bzowej; N. Naoumov; S. Zeuzem; A. Di Bisceglie; G. C. Chao; B. A. Fielman Constance; N. A. Brown; S. Globe View Abstract PDF |
| Adrian M. Di Bisceglie, MD, FACP | 112. Telbivudine GLOBE Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-Year Efficacy in Nucleoside-Treated Hepatitis B Patients . A. DiBisceglie; C. Lai; E. Gane; Y. Chen; S. Thongsawat; Y. Wang; Y. Chen; E. J. Heathcote; S. Zeuzem; . The GLOBE View Abstract PDF |
| Douglas T. Dieterich, MD | 93. Valopicitabine (NM283) plus Peg-Interferon in Treatment-Naive Hepatitis C Patients with HCV Genotype-1 Infection: HCV RNA Clearance During 24 Weeks of Treatment. E. Lawitz; T. Nguyen; Z. Younes; J. Santoro; N. Gitlin; D. McEniry; R. Chasen; J. Goff; S. Knox; K. Kleber; B. Belanger; N. A. Brown; D. Dieterich; I. The 006 View Abstract PDF |
| Ira M. Jacobson, MD | 96. Early Viral Response and On Treatment Response to CPG 10101 (ACTILONTM), in combination with pegylated interferon and/or ribavirin, in chronic HCV genotype 1 infected patients with prior relapse response . I. M. Jacobson; R. Ghalib; E. Lawitz; B. Freilich; S. C. Gordon; P. Kwo; T. R. Riley; D. Bright; M. L. Morris; M. Al-Adhami; J. L. Himes; F. E. Massari; J. G. McHutchison View Abstract PDF |
Top |
|
| Part 4: Views on Combination Therapy for HBV & HCV |
|
| Presenter | Poster |
| Pietro Lampertico, MD | 989. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. P. Lampertico; M. Vigano; M. Iavarone; E. Manenti; G. Lunghi; E. Del Ninno; M. Colombo View Abstract PDF |
| Pietro Lampertico, MD | LB5. Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBEAG-negative chronic hepatitis B. Pietro Lampertico, Alfredo
Marzano, Massimo Levrero, Teresa Santantonio, Vito Di Marco, Maurizia Brunetto, Pietro Andreone, Evangelista Sagnelli, Stefano Fagiuoli, Giuseppe Mazzella, Giovanni Raimondo, Giovannibattista Gaeta, Antonio Ascione, Adefovir Study Group View Abstract PDF |
| John G. McHutchison, MD, FRACP | 927. Current status of subjects receiving Peg-Interferon-Alfa-2a (Peg-IFN) and Ribavirin (RBV) Follow-on therapy after 28-Day treatment with the hepatitis C protease inhibitor TELAPREVIR (VX-950), Peg-IFN AND RBV. M. Rodriguez-Torres; E. Lawitz; A. Muir; J. Keane; T. Kieffer; L. McNair; J. G. McHutchison View Abstract PDF |
| Ira M. Jacobson, MD | 369. Response to Peginterferon Alfa-2b and Ribavirin for Chronic Hepatitis C in Patients with Body Weight >125 kg: Results from the WIN-R Trial. I.M. Jacobson; R. Brown; B. Freilich; N. Afdhal; P. Kwo; J. Santoro; S. Becker; A. Wakil; L. Griffel; C. Brass; The WIN-R Study Group. View Abstract PDF |
| Ira M. Jacobson, MD | 349. Prospective Analysis of Sustained Virologic Response (SVR) to Peg-interferon (PEG IFN) Alfa-2b and Ribavirin Treatment in Asian and Hispanic Patients with Chronic Hepatitis C: Results from the WIN-R Trial. B. Freilich; K. Hu; I. Jacobson; R. Brown; N. Afdhal; P. Kwo; J. Santoro; S. Becker; A. Wakil; D. Pound; E. Godofsky; R. Strauss; D. Bernstein; S. Flamm; N. Bala; V. Araya; L. Griffel; C. Brass View Abstract PDF |
| Ira M. Jacobson, MD | 338. Pegylated Interferon Alfa 2B + Ribavirin are Equally Efficacious and Well Tolerated in Patients >65 Years Old in Comparison to Other Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R Trial) S.L. Flamm; I. Jacobson; R. Brown; B. Freilich; N. Afdhal; P. Kwo; J. Santoro; S. Becker; A. Wakil; D. Pound; J. Harvey; LH. Griffel; C.A. Brass View Abstract PDF |
Top |
|
